TY - JOUR
T1 - Host stress proteins shape hemorrhagic shock via gut microbiota
T2 - evidence from Mendelian randomization and animal models
AU - Deng, Gaorong
AU - Wu, Liping
AU - Xiong, Shui
AU - Zhou, Junxin
AU - Li, Zongfang
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: Hemorrhagic shock (HS) is a severe condition involving stress proteins, inflammation, and gut microbiota dysbiosis. Understanding whether regulatory proteins influence HS through microbial pathways is crucial for improving therapeutic strategies. Methods: We used Mendelian randomization (MR) combined with animal experiments to investigate the role of regulatory proteins in HS. Two-sample MR was performed to assess the impact of various stress-related proteins. Additionally, 16 S rRNA sequencing was conducted in a rat HS model to analyze gut microbiota diversity and composition at baseline, 24 h, and 72 h after hemorrhage. Results: Two-sample MR identified HSPB1 and HIF1A as protective proteins, while APAF1, F7, and F10 increased susceptibility to HS. In the rat model, microbiota alpha diversity decreased at 24 h but partially recovered by 72 h, with significant shifts in beta diversity. Genus-level analysis revealed transient expansion of Lactobacillus, followed by dominance of Blautia and Romboutsia. Stage-specific predictions from PICRUSt2 suggested enrichment of amino acid metabolism and protein synthesis, particularly at 72 h, implicating microbial regulation in cellular recovery and stress adaptation. Conclusions: Our findings support a “protein-microbiota-HS” regulatory framework, highlighting the gut microbiota as key mediators of host stress responses. This integrative approach provides mechanistic insights into HS pathogenesis and suggests potential microbiome-targeted therapeutic strategies. We propose that targeting specific microbial communities, such as Blautia and Lactobacillus, could enhance recovery from HS.
AB - Background: Hemorrhagic shock (HS) is a severe condition involving stress proteins, inflammation, and gut microbiota dysbiosis. Understanding whether regulatory proteins influence HS through microbial pathways is crucial for improving therapeutic strategies. Methods: We used Mendelian randomization (MR) combined with animal experiments to investigate the role of regulatory proteins in HS. Two-sample MR was performed to assess the impact of various stress-related proteins. Additionally, 16 S rRNA sequencing was conducted in a rat HS model to analyze gut microbiota diversity and composition at baseline, 24 h, and 72 h after hemorrhage. Results: Two-sample MR identified HSPB1 and HIF1A as protective proteins, while APAF1, F7, and F10 increased susceptibility to HS. In the rat model, microbiota alpha diversity decreased at 24 h but partially recovered by 72 h, with significant shifts in beta diversity. Genus-level analysis revealed transient expansion of Lactobacillus, followed by dominance of Blautia and Romboutsia. Stage-specific predictions from PICRUSt2 suggested enrichment of amino acid metabolism and protein synthesis, particularly at 72 h, implicating microbial regulation in cellular recovery and stress adaptation. Conclusions: Our findings support a “protein-microbiota-HS” regulatory framework, highlighting the gut microbiota as key mediators of host stress responses. This integrative approach provides mechanistic insights into HS pathogenesis and suggests potential microbiome-targeted therapeutic strategies. We propose that targeting specific microbial communities, such as Blautia and Lactobacillus, could enhance recovery from HS.
KW - 16S rRNA sequencing
KW - Apoptosis
KW - Biomarkers
KW - Gut microbiota
KW - Heat shock proteins
KW - Hemorrhagic shock
KW - Hypoxia-inducible factors
KW - Probiotics
KW - Short-chain fatty acids (SCFAs)
UR - https://www.scopus.com/pages/publications/105022522847
U2 - 10.1186/s12967-025-07364-8
DO - 10.1186/s12967-025-07364-8
M3 - 文章
C2 - 41267045
AN - SCOPUS:105022522847
SN - 1479-5876
VL - 23
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 1324
ER -